Opportunities in viral vector manufacturing arise from rising demand for GMP-grade materials and increasing gene therapy ...
Gene therapy has emerged as a cutting-edge modality with transformative potential for treating a broad range of genetic disorders. Despite significant advancements, the purification and separation of ...
Receiving a platform technology designation from the FDA is a tremendous milestone for our development team and Krystal, both as recognition of the reproducibility and scalability of our HSV-1 gene ...
The signing took place at KFSHRC's pavilion during the Global Health Exhibition 2025, with signatories: Dr. Majid Alfayyadh, ...
OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’s previously announced strategy to add US GMP capacity across ...
Thermo Fisher Scientific Inc., the world leader in serving science, today announced that Dr. Park, an emerging viral vector contract development and manufacturing organization (CDMO) based in South ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback